NCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
Clinical Trials
13 trialsNCT05059327 2025-06-04
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Noema Pharma AG
Phase 2 Completed
NCT02849457 2024-08-19
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
University of Alabama at Birmingham
Phase 2 Completed
NCT04285346 2023-04-04
TSC
Marinus Pharmaceuticals
Phase 2 Completed
NCT00126672 2022-04-25
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT01526356 2020-10-26
Treatment
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02201212 2020-09-16
Everolimus for Cancer With TSC1 or TSC2 Mutation
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01289912 2018-01-25
TSC
Boston Children's Hospital
Phase 2 Completed
NCT02104011 2018-01-23
STBETA
University Hospital, Bordeaux
Phase 2 Completed
NCT00457808 2007-04-09
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed